Search

Your search keyword '"Tribouley, Catherine"' showing total 18 results
Start Over Author "Tribouley, Catherine"
18 results on '"Tribouley, Catherine"'

2. Supplementary Methods, Tables 2-3, Figures 1-6 from Molecular Signature of Smoking in Human Lung Tissues

Author

Bossé, Yohan, primary, Postma, Dirkje S., primary, Sin, Don D., primary, Lamontagne, Maxime, primary, Couture, Christian, primary, Gaudreault, Nathalie, primary, Joubert, Philippe, primary, Wong, Vivien, primary, Elliott, Mark, primary, van den Berge, Maarten, primary, Brandsma, Corry A., primary, Tribouley, Catherine, primary, Malkov, Vladislav, primary, Tsou, Jeffrey A., primary, Opiteck, Gregory J., primary, Hogg, James C., primary, Sandford, Andrew J., primary, Timens, Wim, primary, Paré, Peter D., primary, and Laviolette, Michel, primary

Published
2023
Full Text
View/download PDF

3. Data from Molecular Signature of Smoking in Human Lung Tissues

Author

Bossé, Yohan, primary, Postma, Dirkje S., primary, Sin, Don D., primary, Lamontagne, Maxime, primary, Couture, Christian, primary, Gaudreault, Nathalie, primary, Joubert, Philippe, primary, Wong, Vivien, primary, Elliott, Mark, primary, van den Berge, Maarten, primary, Brandsma, Corry A., primary, Tribouley, Catherine, primary, Malkov, Vladislav, primary, Tsou, Jeffrey A., primary, Opiteck, Gregory J., primary, Hogg, James C., primary, Sandford, Andrew J., primary, Timens, Wim, primary, Paré, Peter D., primary, and Laviolette, Michel, primary

Published
2023
Full Text
View/download PDF

5. The preclinical efficacy, selectivity and pharmacologic profile of MK-5932, an insulin-sparing selective glucocorticoid receptor modulator

Author

Brandish, Philip E., Anderson, Kenneth, Baltus, Gretchen A., Bai, Chang, Bungard, Christopher J., Bunting, Patricia, Byford, Alan, Chiu, Chi-Sung, Cicmil, Milenko, Corcoran, Halea, Euler, Danielle, Fisher, John E., Gambone, Carlo, Hasbun-Manning, Martha, Kuklin, Nelly, Landis, Elizabeth, Lifsted, Traci Q., McElwee-Witmer, Sheila, McIntosh, Ian S., Meissner, Robert S., Miao, John, Mitchell, Helen J., Musselman, Amy, Schmidt, Azriel, Shin, John, Szczerba, Peter, Thompson, Charles D., Tribouley, Catherine, Vogel, Robert L., Warrier, Sudha, and Hershey, James C.

Published
2014
Full Text
View/download PDF

6. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

Author

Orlando, Elena J., Han, Xia, Tribouley, Catherine, Wood, Patricia A., Leary, Rebecca J., Riester, Markus, and Levine, John E.

Subjects
Gene therapy -- Usage, Gene mutation -- Research, Acute lymphocytic leukemia -- Genetic aspects -- Care and treatment, Lymphocytic leukemia, Antigens, Genes, Medical schools, Cancer treatment, Automobiles, Antineoplastic agents, Tumors, Pediatrics, Biological sciences, Health
Abstract

We identified genetic mutations in CD19 and loss of heterozygosity at the time of CD19.sup.- relapse to chimeric antigen receptor (CAR) therapy. The mutations are present in the vast majority of resistant tumor cells and are predicted to lead to a truncated protein with a nonfunctional or absent transmembrane domain and consequently to a loss of surface antigen. This irreversible loss of CD19 advocates for an alternative targeting or combination CAR approach. Mutations in the CD19 gene suggesting irreversible loss of its surface expression are identified in the majority of analyzed cases of CD19.sup.- relapse in two clinical trials of pediatric ALL CD19 CAR T therapy, offering considerations for the rational choice of follow-up therapies., Author(s): Elena J. Orlando [sup.1] , Xia Han [sup.2] , Catherine Tribouley [sup.2] , Patricia A. Wood [sup.2] , Rebecca J. Leary [sup.1] , Markus Riester [sup.1] , John E. [...]

Published
2018
Full Text
View/download PDF

11. Quantitative Multiplexed Immunohistochemistry Assays for Exploring CAR Modified T Cells and Checkpoint Inhibitors in Lymphoma Trials

Author

Tran, Thai Hong, primary, Scott, Krupa, additional, Lee, Shyun-Shyun, additional, Singh, Reshma, additional, Cogan, Shawn, additional, Bordeaux, Jennifer, additional, Jennifer, Hummel, additional, Lameh, Jelveh, additional, Tribouley, Catherine, additional, Kassim, Sadik, additional, Tangri, Shabnam, additional, and Dakappagari, Naveen, additional

Published
2015
Full Text
View/download PDF

12. Molecular Signature of Smoking in Human Lung Tissues

Author

Bossé, Yohan, primary, Postma, Dirkje S., additional, Sin, Don D., additional, Lamontagne, Maxime, additional, Couture, Christian, additional, Gaudreault, Nathalie, additional, Joubert, Philippe, additional, Wong, Vivien, additional, Elliott, Mark, additional, van den Berge, Maarten, additional, Brandsma, Corry A., additional, Tribouley, Catherine, additional, Malkov, Vladislav, additional, Tsou, Jeffrey A., additional, Opiteck, Gregory J., additional, Hogg, James C., additional, Sandford, Andrew J., additional, Timens, Wim, additional, Paré, Peter D., additional, and Laviolette, Michel, additional

Published
2012
Full Text
View/download PDF

14. Effects Of Single Doses Of Oral Corticosteroid On Biomarkers Of Nasal Allergen Challenge (NAC)

Author

Carayannopoulos, Leonidas N., primary, Ruddy, Marcella, additional, Leaker, Brianr R., additional, Calder, Nicole A., additional, Mogg, Robin, additional, Nicholson, Grant C., additional, Imrie, margaret, additional, Chung, Hyun, additional, Bolognese, James A., additional, De Lepeleire, Inge, additional, Swift, Gerry, additional, Tan, Andrew J., additional, Tribouley, Catherine, additional, Tokiwa, George Y., additional, and Hansel, Trevor T., additional

Published
2010
Full Text
View/download PDF

15. Allergen-induced RNA Signature Identified In Induced Sputum And In Whole Blood From Allergic Asthmatics Is Modulated By A Short Course Of Inhaled Fluticasone

Author

Tribouley, Catherine, primary, Zuiker, R., additional, Boot, D, additional, Malkov, Vladislav, additional, Hu, Peter H., additional, Van Dyck, Kristien, additional, Rivas, Veronica, additional, Tokiwa, G, additional, De Lepeleire, Inge, additional, Diamant, Zuzana, additional, and Ruddy, Marcella, additional

Published
2010
Full Text
View/download PDF

18. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.

Author

Jianxiang Wang, Zhi-Xiang Shen, Giuseppe Saglio, Jie Jin, He Huang, Yu Hu, Xin Du, Jianyong Li, Fanyi Meng, Huanling Zhu, Jianda Hu, Jianmin Wang, Ming Hou, Sabine Hertle, Menssen, Hans D., Ortmann, Christine-Elke, Tribouley, Catherine, Ye Yuan, Baccarani, Michele, and Xiaojun Huang

Subjects
*NILOTINIB, *ANTINEOPLASTIC agents, *CHRONIC myeloid leukemia, *TREATMENT of chronic myeloid leukemia, *MYELOID leukemia, *PATIENTS, *DIAGNOSIS
Abstract

Treatment with a tyrosine kinase inhibitor (TKI) targeting BCR-ABL1 is currently the standard of care for patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP). In this study, we present results of the ENESTchina (Evaluating Nilotinib Efficacy and Safety in Clinical Trials-China) that was conducted to investigate nilotinib 300 mg twice daily vs imatinib 400 mg once daily in a Chinese population. ENESTchina met its primary end point with a statistically significant higher rate of major molecular response (MMR; BCR-ABL1 ⩽0.1% on the International Scale) at 12 months in the nilotinib arm vs the imatinib arm (52.2% vs 27.8%; P < .0001), and MMR rates remained higher with nilotinib vs imatinib throughout the follow-up period. Rates of complete cytogenetic response (0% Philadelphia chromosome-positive [Ph+] metaphases by standard cytogenetics) were comparable and ⩾80% by 24 months in both arms. The estimated rate of freedom from progression to accelerated phase/blast crisis at 24 months was 95.4% in each arm. The safety profiles of both drugs were similar to those from previous studies. In conclusion, rates of MMR at 12 months were superior with nilotinib vs imatinib in Chinese patients with newly diagnosed Ph+ CML-CP. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results